Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 3.0 | 5.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 2.07 | 1.36 |
NAV | ₹48.38 | ₹202.57 |
Fund Started | 02 Mar 2020 | 07 May 2007 |
Fund Size | ₹1550.58 Cr | ₹84854.73 Cr |
Exit Load | Exit load of 1%, if redeemed within 15 days. | Exit load of 1% if redeemed within 1 year. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 7.52% | 9.49% |
3 Year | 19.06% | 25.54% |
5 Year | 25.05% | 29.55% |
1 Year
3 Year
5 Year
Equity | 96.24% | 93.60% |
Cash | 3.71% | 6.40% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Max Financial Services Ltd. | 3.00% |
The Federal Bank Ltd. | 2.81% |
Nippon Life India Asset Management Ltd. | 2.53% |
Kei Industries Ltd. | 2.46% |
Cummins India Ltd. | 2.38% |
Dixon Technologies (India) Ltd. | 2.32% |
Fortis Healthcare Ltd. | 2.19% |
GE Vernova T&D India Ltd | 2.14% |
CG Power and Industrial Solutions Ltd. | 2.05% |
Indian Bank | 2.01% |
Name | Assets |
|---|---|
Max Financial Services Ltd. | 4.76% |
Balkrishna Industries Ltd. | 3.54% |
Indian Bank | 3.26% |
Fortis Healthcare Ltd. | 3.18% |
AU Small Finance Bank Ltd. | 3.16% |
Coforge Ltd. | 2.93% |
The Federal Bank Ltd. | 2.91% |
Hindustan Petroleum Corporation Ltd. | 2.90% |
Glenmark Pharmaceuticals Ltd. | 2.87% |
Ipca Laboratories Ltd. | 2.80% |
Name | Pratik Dharmshi | Chirag Setalvad |
Start Date | 01 Sep 2025 | 28 Jun 2014 |
Name
Start Date
Description | The Scheme seeks to achieve long term capital appreciation and generate income by investing predominantly in equity and equity related securities of mid cap companies. | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. |
Launch Date | 02 Mar 2020 | 07 May 2007 |
Description
Launch Date